Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer

J Control Release. 2013 Nov 10;171(3):339-48. doi: 10.1016/j.jconrel.2013.04.026. Epub 2013 May 9.

Abstract

The co-delivery of drug combination at a controlled ratio via the same vehicle to the cancer cells is offering the advantages such as spatial-temporal synchronization of drug exposure, synergistic therapeutic effects and increased therapeutic potency. In an attempt to develop such multidrug vehicle this work focuses on functional biodegradable and biocompatible polypeptide-based polymeric micelles. Triblock copolymers containing the blocks of ethylene glycol, glutamic acid and phenylalanine (PEG-PGlu-PPhe) were successfully synthesized via NCA-based ring-opening copolymerization and their composition was confirmed by (1)H NMR. Self-assembly behavior of PEG-PGlu90-PPhe25 was utilized for the synthesis of hybrid micelles with PPhe hydrophobic core, cross-linked ionic PGlu intermediate shell layer, and PEG corona. Cross-linked (cl) micelles were about 90nm in diameter (ξ-potential=-20mV), uniform (narrow size distribution), and exhibited nanogels-like behavior. Degradation of cl-micelles was observed in the presence of proteolytic enzymes (cathepsin B). The resulting cl-micelles can incorporate the combination of drugs with very different physical properties such as cisplatin (15 w/w% loading) and paclitaxel (9 w/w% loading). Binary drug combination in cl-micelles exhibited synergistic cytotoxicity against human ovarian A2780 cancer cells and exerted a superior antitumor activity by comparison to individual drug-loaded micelles or free cisplatin in cancer xenograft model in vivo. Tunable composition and stability of these hybrid biodegradable micelles provide platform for drug combination delivery in a broad range of cancers.

Keywords: Cisplatin; Combination drug delivery; Controlled release; Cross-linked polymer micelles; Ovarian cancer; Paclitaxel.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Cell Line, Tumor
  • Cisplatin / administration & dosage*
  • Cisplatin / therapeutic use
  • Delayed-Action Preparations / chemistry*
  • Female
  • Glutamic Acid / chemistry
  • Humans
  • Mice
  • Mice, Nude
  • Micelles*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Ovary / drug effects
  • Ovary / pathology
  • Paclitaxel / administration & dosage*
  • Paclitaxel / therapeutic use
  • Phenylalanine / chemistry
  • Polyethylene Glycols / chemistry

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Micelles
  • Glutamic Acid
  • Polyethylene Glycols
  • Phenylalanine
  • Paclitaxel
  • Cisplatin